Dutch biotech scores €25M in small molecule bet to tackle lysosomal storage disorders
While a host of biotech companies work on gene and enzyme replacement therapies for certain lysosomal storage disorders, a Dutch player is aiming to slot in its small molecule approach across a range of these rare inherited metabolic disorders.
The company — Azafaros — founded in 2018 based on science developed from Leiden University and Amsterdam University Medical Center has secured €25 million in Series A financing as it works on shepherding its lead experimental drug into the clinic.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.